NASDAQ:CBAY CymaBay Therapeutics (CBAY) Stock Forecast, Price & News $9.42 -0.03 (-0.32%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$9.36▼$9.6350-Day Range$8.50▼$10.8352-Week Range$1.81▼$11.22Volume716,659 shsAverage Volume1.59 million shsMarket Capitalization$918.54 millionP/E RatioN/ADividend YieldN/APrice Target$14.57 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability CymaBay Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.14 Rating ScoreUpside/Downside54.7% Upside$14.57 Price TargetShort InterestHealthy10.39% of Shares Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment1.38Based on 3 Articles This WeekInsider TradingSelling Shares$1.39 M Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.39 out of 5 starsMedical Sector179th out of 981 stocksPharmaceutical Preparations Industry75th out of 468 stocks 3.6 Analyst's Opinion Consensus RatingCymaBay Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.57, CymaBay Therapeutics has a forecasted upside of 54.7% from its current price of $9.42.Amount of Analyst CoverageCymaBay Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted10.39% of the outstanding shares of CymaBay Therapeutics have been sold short.Short Interest Ratio / Days to CoverCymaBay Therapeutics has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in CymaBay Therapeutics has recently decreased by 8.49%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCymaBay Therapeutics does not currently pay a dividend.Dividend GrowthCymaBay Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCymaBay Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for CymaBay Therapeutics is -0.88. Previous Next 3.0 News and Social Media Coverage News SentimentCymaBay Therapeutics has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for CymaBay Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 17 people have searched for CBAY on MarketBeat in the last 30 days. This is a decrease of -35% compared to the previous 30 days.MarketBeat Follows7 people have added CymaBay Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CymaBay Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,390,672.00 in company stock.Percentage Held by InsidersOnly 5.60% of the stock of CymaBay Therapeutics is held by insiders.Percentage Held by Institutions73.54% of the stock of CymaBay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CymaBay Therapeutics are expected to remain at ($1.01) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of CymaBay Therapeutics is -7.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CymaBay Therapeutics is -7.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCymaBay Therapeutics has a P/B Ratio of 21.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About CymaBay Therapeutics (NASDAQ:CBAY) StockCymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.Read More Receive CBAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CBAY Stock News HeadlinesMay 18, 2023 | marketbeat.comThe 10 Top-Rated Stocks by Wall Street Analysts in August 2021 (CBAY)Analyst ratings reflect the sentiment of individuals who have significant knowledge of a company’s operations. For a company to be included on MarketBeat’s top-rated list they must have received at least five ratings within the last 12 months. Here are the 10 companies that have received the highest average rating by Wall Street analysts in August 2021.May 25, 2023 | americanbankingnews.comBrokerages Set CymaBay Therapeutics, Inc. (NASDAQ:CBAY) PT at $14.57June 8, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 24, 2023 | americanbankingnews.comCymaBay Therapeutics (NASDAQ:CBAY) Upgraded to Hold at StockNews.comMay 24, 2023 | americanbankingnews.comCymaBay Therapeutics (NASDAQ:CBAY) Shares Down 4.6% on Insider SellingMay 22, 2023 | americanbankingnews.comInsider Selling: CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Insider Sells 21,749 Shares of StockMay 20, 2023 | americanbankingnews.comCymaBay Therapeutics, Inc. to Post Q2 2023 Earnings of ($0.31) Per Share, SVB Leerink Forecasts (NASDAQ:CBAY)May 20, 2023 | americanbankingnews.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) to Post Q2 2023 Earnings of ($0.27) Per Share, William Blair ForecastsJune 8, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 19, 2023 | finance.yahoo.comWhy CymaBay Therapeutics Stock Nose-Dived This WeekMay 19, 2023 | americanbankingnews.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) General Counsel Sells $51,850.00 in StockMay 17, 2023 | americanbankingnews.comCymaBay Therapeutics (NASDAQ:CBAY) Rating Lowered to Sell at StockNews.comMay 16, 2023 | msn.comOppenheimer Maintains Cymabay Therapeutics (CBAY) Outperform RecommendationMay 16, 2023 | msn.comHC Wainwright & Co. Reiterates Cymabay Therapeutics (CBAY) Buy RecommendationMay 16, 2023 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on CymaBay Therapeutics (CBAY)May 16, 2023 | msn.comExpert Ratings for CymaBay TherapeuticsMay 16, 2023 | finance.yahoo.comCymaBay Therapeutics Inc. (CBAY) Is a Great Choice for 'Trend' Investors, Here's WhyMay 16, 2023 | finance.yahoo.comQ1 2023 CymaBay Therapeutics Inc Earnings CallMay 16, 2023 | markets.businessinsider.comCymaBay Therapeutics (CBAY) Receives a Buy from H.C. WainwrightMay 16, 2023 | americanbankingnews.comCymaBay Therapeutics (NASDAQ:CBAY) Price Target Increased to $15.00 by Analysts at Cantor FitzgeraldMay 16, 2023 | finanznachrichten.deCymaBay Therapeutics, Inc.: CymaBay Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 15, 2023 | finance.yahoo.comCymaBay Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 12, 2023 | msn.comCymaBay Therapeutics's Earnings OutlookMay 10, 2023 | finance.yahoo.comCymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023May 9, 2023 | seekingalpha.comCymaBay Therapeutics: Slow But Steady ProgressMay 9, 2023 | msn.comCymaBay names new finance chiefMay 9, 2023 | finance.yahoo.comCymaBay Names Harish Shantharam Chief Financial OfficerSee More Headlines CBAY Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CBAY Company Calendar Last Earnings3/16/2023Today6/08/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CBAY CUSIPN/A CIK1042074 Webwww.cymabay.com Phone(510) 293-8800Fax510-293-9090Employees59Year FoundedN/APrice Target and Rating Average Stock Price Forecast$14.57 High Stock Price Forecast$19.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+54.7%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,000,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-151.26% Return on Assets-59.11% Debt Debt-to-Equity RatioN/A Current Ratio5.22 Quick Ratio5.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.43 per share Price / Book21.91Miscellaneous Outstanding Shares97,510,000Free Float92,052,000Market Cap$918.54 million OptionableOptionable Beta0.27 Key ExecutivesSujal ShahPresident, Chief Executive Officer & DirectorDaniel MenoldVice President-FinanceHarish ShantharamChief Financial OfficerCharles A. McWherterPresident-Research & DevelopmentPaul T. QuinlanSecretary & Chief Compliance OfficerKey CompetitorsCogent BiosciencesNASDAQ:COGTKura OncologyNASDAQ:KURAEQRxNASDAQ:EQRXInnovivaNASDAQ:INVAEnliven TherapeuticsNASDAQ:ELVNView All CompetitorsInsiders & InstitutionsGolden State Equity PartnersBought 50,000 shares on 6/1/2023Ownership: 0.051%Prelude Capital Management LLCBought 10,973 shares on 6/1/2023Ownership: 0.011%JPMorgan Chase & Co.Bought 539,415 shares on 5/18/2023Ownership: 0.556%Charles McwherterSold 21,749 sharesTotal: $197,480.92 ($9.08/share)Saturn V Capital Management LLCBought 17,686 shares on 5/16/2023Ownership: 1.674%View All Insider TransactionsView All Institutional Transactions CBAY Stock - Frequently Asked Questions Should I buy or sell CymaBay Therapeutics stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last twelve months. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CBAY shares. View CBAY analyst ratings or view top-rated stocks. What is CymaBay Therapeutics' stock price forecast for 2023? 7 Wall Street research analysts have issued 1-year target prices for CymaBay Therapeutics' stock. Their CBAY share price forecasts range from $12.00 to $19.00. On average, they anticipate the company's stock price to reach $14.57 in the next twelve months. This suggests a possible upside of 54.7% from the stock's current price. View analysts price targets for CBAY or view top-rated stocks among Wall Street analysts. How have CBAY shares performed in 2023? CymaBay Therapeutics' stock was trading at $6.27 at the beginning of the year. Since then, CBAY stock has increased by 50.2% and is now trading at $9.42. View the best growth stocks for 2023 here. Are investors shorting CymaBay Therapeutics? CymaBay Therapeutics saw a decline in short interest in May. As of May 15th, there was short interest totaling 10,130,000 shares, a decline of 8.5% from the April 30th total of 11,070,000 shares. Based on an average trading volume of 1,700,000 shares, the short-interest ratio is presently 6.0 days. View CymaBay Therapeutics' Short Interest. When is CymaBay Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our CBAY earnings forecast. How were CymaBay Therapeutics' earnings last quarter? CymaBay Therapeutics, Inc. (NASDAQ:CBAY) issued its quarterly earnings results on Thursday, March, 16th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.30). During the same period in the previous year, the business posted ($0.34) earnings per share. What ETFs hold CymaBay Therapeutics' stock? ETFs with the largest weight of CymaBay Therapeutics (NASDAQ:CBAY) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), SPDR S&P Pharmaceuticals ETF (XPH), Invesco Nasdaq Future Gen 200 ETF (QQQS), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco Raymond James SB-1 Equity ETF (RYJ), ALPS Medical Breakthroughs ETF (SBIO) and iShares Micro-Cap ETF (IWC). What other stocks do shareholders of CymaBay Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX). What is CymaBay Therapeutics' stock symbol? CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY." Who are CymaBay Therapeutics' major shareholders? CymaBay Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (4.01%), Franklin Resources Inc. (3.31%), BlackRock Inc. (2.72%), Bain Capital Life Sciences Investors LLC (2.57%), Commodore Capital LP (2.08%) and Balyasny Asset Management L.P. (2.01%). Insiders that own company stock include Charles Mcwherter, Dennis D Kim, Paul T Quinlan and Sujal Shah. View institutional ownership trends. How do I buy shares of CymaBay Therapeutics? Shares of CBAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CymaBay Therapeutics' stock price today? One share of CBAY stock can currently be purchased for approximately $9.42. How much money does CymaBay Therapeutics make? CymaBay Therapeutics (NASDAQ:CBAY) has a market capitalization of $918.54 million. The biopharmaceutical company earns $-106,000,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. How can I contact CymaBay Therapeutics? CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The official website for the company is www.cymabay.com. The biopharmaceutical company can be reached via phone at (510) 293-8800, via email at investors@cymabay.com, or via fax at 510-293-9090. This page (NASDAQ:CBAY) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CymaBay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.